Nordic ListingsIssuer Report
Bactiguard Holding AB: Quarterly Trading Report 2025 Q3
Bactiguard Holding AB: Quarterly Trading Report 2025 Q3https://view.news.eu.nasdaq.com/view?id=b8922fa414bcf9cb5c314cde5dd146f01&lang=en&src=omxlink
Bactiguard Holding AB: Quarterly Trading Report 2025 Q3
Earlier from Bactiguard
- BACTI_B: License-driven growth and infection-prevention tech set the stage for ambitious 2030 targets
- BACTI_B: EBITDA remained positive as revenues dipped, with strong growth in wound management and new cardiology initiatives
- BACTI_B: Infection prevention technology and strong financial growth underpin ambitious 2030 targets
- BACTI_B: Q1 2025 saw sustained profitability, revenue growth, and robust Wound Management performance
- BACTI_B: Infection prevention technology and MedTech partnerships drive growth and ambitious 2030 targets
Later from Bactiguard
- BACTI_B: Profitability maintained in Q3 2025, with BD rebound and strong wound management growth
- Bactiguard CEO Buys SEK 4.26 Mln Worth of Co Shares
- BACTI_B: Strong Q4 EBITDA and cost discipline offset revenue declines; partnerships and pipeline expanded
- The Nomination Committee's proposal for Board of Directors to the 2026 Annual General Meeting
- Invitation to presentation of Bactiguard’s interim report for the first quarter 2026
Follow Bactiguard into a list and get an email when it puts out news.
Follow Bactiguard